For some reason, a few companies seem to think that including investor infusions while computing profitability is somehow a good thing. It is wise to (gently) probe and figure whether this is what they are doing.
For some reason, a few companies seem to think that including investor infusions while computing profitability is somehow a good thing. It is wise to (gently) probe and figure whether this is what they are doing.